What is Cross Country Healthcare's operating income?

Cross Country Healthcare's total operating income in 2025 was -$84.41 million, based on the following breakdown: Total Gross Profit: $213.57 million Total Operating Expenses: $298.63 million

Cross Country Healthcare (CCRN) Financials

$13.20 -0.02 (-0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$13.20 0.00 (0.00%)

As of 05:23 PM Eastern

Compare

Annual Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	4.42	7.97	38	-17	-58	-13	132	186	73	-15	-95
Consolidated Net Income / (Loss)	4.95	8.73	39	-16	-56	-12	132	186	73	-15	-95
Net Income / (Loss) Continuing Operations	4.95	8.73	39	-16	-56	-12	132	186	73	-15	-95
Total Pre-Tax Income	4.16	4.55	4.30	-18	-24	-12	133	253	103	-16	-84
Total Operating Income	21	6.18	12	-13	-16	-9.16	139	270	113	-17	-84
Total Gross Profit	196	833	863	814	820	833	375	2,794	2,005	1,323	214
Total Revenue	767	834	865	816	822	836	1,677	2,803	2,020	1,344	1,054
Operating Revenue	767	834	865	816	822	836	1,677	2,803	2,020	1,344	1,054
Total Cost of Revenue	571	0.59	1.83	2.20	2.01	3.04	1,302	9.61	15	21	841
Operating Cost of Revenue	570	-	-	-	-	-	1,302	-	-	-	841
Total Operating Expenses	176	827	851	827	836	843	236	2,524	1,892	1,339	299
Selling, General & Admin Expense	161	180	187	180	182	174	216	324	300	233	201
Depreciation Expense	8.07	9.18	10	12	14	13	9.85	13	18	18	17
Other Operating Expenses / (Income)	2.18	613	637	610	618	634	4.78	2,180	1,570	1,081	-0.44
Impairment Charge	2.10	24	14	22	16	16	2.07	5.60	0.72	2.89	78
Restructuring Charge	2.18	0.83	3.00	2.76	3.57	6.05	2.63	1.86	2.61	4.33	3.75
Total Other Income / (Expense), net	-16	-1.64	-7.45	-5.32	-8.50	-3.17	-6.10	-17	-9.90	0.47	0.90
Interest Expense	6.81	7.67	9.18	5.73	7.28	2.89	6.87	18	9.82	2.19	2.22
Interest & Investment Income	-	-	-	-	-	-	-	0.00	0.00	2.05	3.13
Other Income / (Expense), net	-9.60	6.04	1.74	0.42	-1.22	-0.28	0.77	1.33	-0.09	0.61	-0.01
Income Tax Expense	-0.79	-4.19	-35	-2.48	32	-0.19	1.21	67	30	-1.84	11
Basic Earnings per Share	$0.14	$0.25	$1.07	($0.48)	($1.61)	($0.36)	$3.60	$5.02	$2.07	($0.44)	($2.93)
Weighted Average Basic Shares Outstanding	31.51M	32.13M	35.02M	35.66M	35.82M	36.09M	36.69M	37.01M	35.16M	33.38M	32.41M
Diluted Earnings per Share	$0.14	$0.15	$1.01	($0.48)	($1.61)	($0.36)	$3.53	$4.95	$2.05	($0.44)	($2.93)
Weighted Average Diluted Shares Outstanding	32.16M	36.25M	36.17M	35.66M	35.82M	36.09M	37.39M	37.54M	35.48M	33.38M	32.41M
Weighted Average Basic & Diluted Shares Outstanding	31.60M	31.90M	35.10M	35.66M	35.82M	36.09M	38.06M	36.82M	34.73M	32.81M	32.32M

This table shows Cross Country Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	13	9.04	2.69	-16	2.56	-3.75	-0.49	-6.66	-4.77	-83	-4.27
Consolidated Net Income / (Loss)	13	9.04	2.69	-16	2.56	-3.75	-0.49	-6.66	-4.77	-83	-4.27
Net Income / (Loss) Continuing Operations	13	9.04	2.69	-16	2.56	-3.75	-0.49	-6.66	-4.77	-83	-4.27
Total Pre-Tax Income	20	13	3.69	-20	3.39	-3.91	-0.90	-5.73	-5.64	-71	-3.73
Total Operating Income	20	13	2.92	-19	2.85	-3.43	-0.98	-5.86	-5.97	-72	-4.16
Total Gross Profit	440	410	378	321	314	310	293	274	251	-605	241
Total Revenue	442	414	379	340	315	310	293	274	250	237	241
Operating Revenue	442	414	379	340	315	310	293	274	250	237	241
Total Cost of Revenue	2.36	4.17	1.29	19	1.51	-0.23	0.04	0.03	-0.86	842	0.06
Other Cost of Revenue	2.36	4.17	1.29	19	1.51	-0.23	0.04	0.03	-0.86	-	0.06
Total Operating Expenses	420	396	375	340	311	314	294	280	257	-533	245
Selling, General & Admin Expense	70	68	63	60	54	56	52	50	47	51	46
Depreciation Expense	4.54	4.47	4.64	4.72	4.50	4.34	4.77	4.10	4.09	3.83	3.67
Other Operating Expenses / (Income)	345	324	306	273	251	247	235	225	200	-661	195
Impairment Charge	0.19	-	0.60	0.11	0.00	2.17	0.00	0.00	0.00	78	0.23
Restructuring Charge	0.35	0.92	0.94	2.12	1.00	4.50	2.34	0.59	5.68	-4.86	0.76
Total Other Income / (Expense), net	-0.80	-0.54	0.77	-0.36	0.54	-0.48	0.08	0.13	0.34	0.36	0.42
Interest Expense	0.67	0.59	0.46	0.57	0.55	0.61	0.54	0.55	0.56	0.57	0.57
Interest & Investment Income	0.01	-	0.17	0.24	1.11	-	0.68	0.70	0.86	0.88	0.97
Other Income / (Expense), net	-0.14	0.05	1.06	-0.02	-0.02	-0.82	-0.06	-0.02	0.03	0.05	0.01
Income Tax Expense	6.69	3.93	1.00	-3.51	0.83	-0.16	-0.41	0.93	-0.86	12	0.53
Basic Earnings per Share	$0.37	$0.28	$0.08	($0.47)	$0.08	($0.13)	($0.02)	($0.20)	($0.15)	($2.56)	($0.14)
Weighted Average Basic Shares Outstanding	34.95M	35.16M	34.22M	33.96M	33.02M	33.38M	32.28M	32.49M	32.52M	32.41M	31.47M
Diluted Earnings per Share	$0.36	$0.28	$0.08	($0.47)	$0.08	($0.13)	($0.02)	($0.20)	($0.15)	($2.56)	($0.14)
Weighted Average Diluted Shares Outstanding	35.15M	35.48M	34.60M	33.96M	33.06M	33.38M	32.28M	32.49M	32.52M	32.41M	31.47M
Weighted Average Basic & Diluted Shares Outstanding	35.15M	34.73M	34.77M	33.81M	32.92M	32.81M	32.78M	32.76M	32.76M	32.32M	32.33M

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-2.54	18	4.91	-9.52	-15	0.57	-0.56	2.57	13	65	27
Net Cash From Operating Activities	18	30	46	21	5.54	27	-86	134	248	120	48
Net Cash From Continuing Operating Activities	18	30	46	21	5.54	27	-86	134	248	120	48
Net Income / (Loss) Continuing Operations	4.95	8.73	39	-16	-56	-12	132	186	73	-15	-95
Consolidated Net Income / (Loss)	4.95	8.73	39	-16	-56	-12	132	186	73	-15	-95
Depreciation Expense	8.07	9.18	10	12	14	13	9.85	13	18	18	17
Non-Cash Adjustments To Reconcile Net Income	18	28	27	36	30	25	13	29	24	28	84
Changes in Operating Assets and Liabilities, net	-15	-18	-31	-11	17	2.09	-240	-94	133	88	43
Net Cash From Investing Activities	-24	-9.78	-91	-6.68	-2.94	-4.62	-34	-44	-14	-8.71	-8.16
Net Cash From Continuing Investing Activities	-24	-9.78	-91	-6.68	-2.94	-4.62	-34	-44	-14	-8.71	-8.16
Purchase of Property, Plant & Equipment	-2.36	-6.52	-5.11	-4.60	-2.94	-4.62	-7.17	-8.79	-14	-8.71	-8.16
Other Investing Activities, net	-	-	-	-	-	0.00	1.09	0.09	0.20	0.00	0.00
Net Cash From Financing Activities	3.36	-2.16	51	-24	-18	-22	119	-88	-221	-47	-13
Net Cash From Continuing Financing Activities	3.36	-2.16	51	-24	-18	-22	119	-88	-221	-47	-13
Repayment of Debt	-60	-102	-49	-18	-92	-440	-497	-1,740	-872	-18	-1.45
Repurchase of Common Equity	-	0.00	0.00	-5.00	-	0.00	0.00	-35	-58	-37	-6.83
Issuance of Debt	64	100	101	0.00	77	420	619	1,700	721	18	1.45
Other Financing Activities, net	-0.54	-	-	-	-0.80	-0.74	-2.23	-13	-12	-9.54	-6.17
Other Net Changes in Cash	-	-	-	-	-	-0.01	0.01	-0.01	0.01	-0.01	0.02
Cash Interest Paid	5.05	3.89	3.41	6.34	4.55	2.67	5.77	13	7.53	1.37	1.40
Cash Income Taxes Paid	1.04	1.77	0.70	1.04	0.56	0.61	3.61	83	22	2.43	-5.69

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	14	2.79	-12	64	-5.58	18	-0.94	0.50	18	9.61	-3.15
Net Cash From Operating Activities	70	12	6.01	82	7.47	24	5.68	4.22	20	18	4.77
Net Cash From Continuing Operating Activities	70	12	6.01	82	7.47	24	5.68	4.22	20	18	4.77
Net Income / (Loss) Continuing Operations	13	9.04	2.69	-16	2.56	-3.75	-0.49	-6.66	-4.77	-83	-4.27
Consolidated Net Income / (Loss)	13	9.04	2.69	-16	2.56	-3.75	-0.49	-6.66	-4.77	-83	-4.27
Depreciation Expense	4.54	4.47	4.64	4.72	4.50	4.34	4.77	4.10	4.09	3.83	3.67
Non-Cash Adjustments To Reconcile Net Income	5.98	1.15	3.42	22	0.53	2.34	1.64	-0.01	-0.39	82	1.45
Changes in Operating Assets and Liabilities, net	47	-2.58	-4.74	72	-0.11	21	-0.24	6.79	21	15	3.92
Net Cash From Investing Activities	-3.41	-2.88	-2.21	-2.85	-1.12	-2.53	-1.89	-1.97	-2.19	-2.12	-1.46
Net Cash From Continuing Investing Activities	-3.41	-2.88	-2.21	-2.85	-1.12	-2.53	-1.89	-1.97	-2.19	-2.12	-1.46
Purchase of Property, Plant & Equipment	-3.43	-2.88	-2.21	-2.85	-1.12	-2.53	-1.89	-1.97	-2.19	-2.12	-1.46
Net Cash From Financing Activities	-53	-6.42	-16	-15	-12	-4.08	-4.73	-1.76	-0.01	-6.52	-6.46
Net Cash From Continuing Financing Activities	-53	-6.42	-16	-15	-12	-4.08	-4.73	-1.76	-0.01	-6.52	-6.46
Repayment of Debt	-143	-56	-14	-3.15	-0.35	-0.35	-0.37	-0.36	-0.36	-0.37	-0.37
Repurchase of Common Equity	-15	-6.40	-6.37	-15	-12	-4.08	-0.31	-	-	-6.52	-5.87
Issuance of Debt	112	56	14	3.15	0.35	0.35	0.37	0.36	0.36	0.37	0.37
Other Financing Activities, net	-7.51	-0.01	-9.29	-0.25	-0.01	-	-4.41	-1.76	-0.01	-	-0.59
Other Net Changes in Cash	-	-	-	-	-	-0.01	-	-	0.02	0.00	-0.01

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	366	388	468	427	382	357	733	950	681	589	449
Total Current Assets	159	206	209	195	183	183	508	677	417	335	294
Cash & Equivalents	2.45	21	26	16	1.03	1.60	1.04	3.60	17	82	109
Accounts Receivable	147	174	174	166	170	170	494	642	372	223	168
Prepaid Expenses	4.52	6.13	5.29	6.21	6.10	5.46	7.65	11	7.68	7.85	7.56
Current Deferred & Refundable Income Taxes	-	-	-	-	-	-	0.00	13	8.62	10	3.59
Other Current Assets	4.90	5.24	4.46	6.55	6.70	6.05	5.68	8.48	11	12	6.18
Plant, Property, & Equipment, net	10	13	14	14	12	12	16	20	27	29	28
Total Noncurrent Assets	196	170	245	218	187	162	209	253	237	225	128
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	14	23	26	21	15
Goodwill	95	80	118	101	101	91	119	163	135	135	64
Intangible Assets	83	72	88	76	51	41	48	45	54	42	28
Employee Benefit Assets	-	-	-	-	-	-	-	-	-	2.89	2.94
Other Noncurrent Operating Assets	18	18	19	18	35	30	15	14	15	16	18
Total Liabilities & Shareholders' Equity	366	388	468	427	382	357	733	950	681	589	449
Total Liabilities	224	237	230	209	219	202	435	498	213	170	126
Total Current Liabilities	86	97	95	85	85	93	200	279	156	120	78
Accounts Payable	41	59	51	44	46	50	110	193	93	65	46
Current Employee Benefit Liabilities	29	33	34	33	31	36	66	73	52	48	28
Other Current Liabilities	5.29	2.75	2.85	3.08	8.43	5.57	5.45	6.03	4.16	3.40	3.34
Total Noncurrent Liabilities	138	139	135	123	133	109	236	70	57	50	48
Noncurrent Deferred & Payable Income Tax Liabilities	18	13	-	0.10	7.52	6.59	8.99	7.65	11	11	13
Noncurrent Employee Benefit Liabilities	-	-	-	-	-	-	-	-	-	2.93	2.59
Other Noncurrent Operating Liabilities	38	42	43	45	55	49	50	63	47	36	33
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	141	152	238	218	164	155	298	451	468	419	323
Total Preferred & Common Equity	141	151	237	218	163	154	298	451	468	419	323
Total Common Equity	141	151	237	218	163	154	298	451	468	419	323
Common Stock	254	257	305	303	306	310	322	293	236	202	201
Retained Earnings	-112	-104	-67	-84	-142	-155	-23	160	233	218	123
Accumulated Other Comprehensive Income / (Loss)	-1.21	-1.24	-1.17	-1.46	-1.24	-1.28	-1.29	-1.39	-1.39	-1.44	-1.56

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	883	921	771	708	648	603	597	576	554	538	451
Total Current Assets	660	649	506	445	387	338	337	325	309	295	298
Cash & Equivalents	30	0.29	0.67	14	5.24	70	64	81	81	99	106
Accounts Receivable	611	627	485	410	357	242	245	220	202	180	177
Prepaid Expenses	3.95	11	6.75	4.78	7.62	6.25	4.55	8.30	8.04	5.29	7.41
Current Deferred & Refundable Income Taxes	-	1.78	4.13	5.24	6.33	8.97	10	5.89	5.39	3.76	3.07
Other Current Assets	15	8.53	9.20	11	11	11	13	11	13	6.72	5.60
Plant, Property, & Equipment, net	19	23	25	26	28	29	29	28	28	28	27
Total Noncurrent Assets	204	249	241	236	233	236	232	223	217	215	125
Noncurrent Note & Lease Receivables	21	23	22	22	23	23	22	20	16	15	14
Goodwill	113	142	137	135	135	135	135	135	135	135	64
Intangible Assets	47	63	60	57	52	49	46	40	38	36	26
Employee Benefit Assets	-	-	-	-	-	-	-	-	-	-	2.87
Other Noncurrent Operating Assets	14	14	14	15	16	18	19	19	19	20	19
Total Liabilities & Shareholders' Equity	883	921	771	708	648	603	597	576	554	538	451
Total Liabilities	460	469	301	238	180	164	173	158	142	130	138
Total Current Liabilities	277	265	216	184	128	110	121	109	96	86	91
Accounts Payable	192	177	140	115	69	56	58	56	49	42	48
Current Employee Benefit Liabilities	71	70	56	57	52	47	54	50	45	42	40
Other Current Liabilities	6.29	5.84	4.65	4.45	3.82	3.72	3.86	2.67	1.90	1.38	3.45
Total Noncurrent Liabilities	183	204	85	55	52	54	52	49	45	45	48
Noncurrent Deferred & Payable Income Tax Liabilities	0.24	8.43	9.19	9.91	11	12	11	10	10	10	13
Noncurrent Employee Benefit Liabilities	-	-	-	-	-	-	-	-	-	-	2.24
Other Noncurrent Operating Liabilities	53	57	45	45	40	42	39	39	35	34	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	423	452	470	470	468	439	425	418	412	408	313
Total Preferred & Common Equity	423	452	470	470	468	439	425	418	412	408	313
Total Common Equity	423	452	470	470	468	439	425	418	412	408	313
Common Stock	297	258	255	242	229	215	204	202	203	204	196
Retained Earnings	127	195	217	229	241	225	222	218	211	206	119
Accumulated Other Comprehensive Income / (Loss)	-1.37	-1.38	-1.38	-1.39	-1.39	-1.39	-1.40	-1.44	-1.44	-1.53	-1.69

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	32,574,260.00	33,010,910.00	36,480,911.00	36,250,734.00	36,877,022.00	37,563,384,000.00	38,003,670,000.00	-	-	-	32,759,952.00
DEI Adjusted Shares Outstanding	32,574,260.00	33,010,910.00	36,480,911.00	36,250,734.00	36,877,022.00	37,563,384,000.00	38,003,670,000.00	-	-	-	32,759,952.00
DEI Earnings Per Adjusted Shares Outstanding	0.14	0.24	1.03	-0.47	-1.57	0.00	0.00	-	-	-	-2.90
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	24.21%	8.62%	3.78%	-5.61%	0.70%	1.73%	100.46%	67.20%	-27.95%	-33.46%	-21.56%
EBITDA Growth	212.16%	10.55%	5.10%	-102.81%	-318.18%	213.29%	4,540.24%	89.28%	-53.85%	-98.52%	-3,586.03%
EBIT Growth	140.39%	11.39%	10.35%	-192.42%	-35.83%	44.23%	1,583.83%	93.62%	-58.47%	-114.44%	-419.21%
NOPAT Growth	434.22%	-51.49%	792.17%	-108.51%	-21.98%	41.70%	2,252.88%	43.66%	-59.88%	-114.84%	-400.53%
Net Income Growth	115.71%	76.24%	344.42%	-140.51%	-255.94%	78.30%	1,187.15%	40.89%	-60.95%	-120.04%	-551.64%
EPS Growth	113.73%	7.14%	573.33%	-147.52%	-235.42%	77.64%	1,080.56%	40.23%	-58.59%	-121.46%	-565.91%
Operating Cash Flow Growth	547.81%	65.31%	50.96%	-53.86%	-73.61%	390.87%	-414.73%	256.57%	85.38%	-51.66%	-59.83%
Free Cash Flow Firm Growth	99.26%	6,380.16%	-40.53%	31.93%	141.52%	-56.28%	-867.83%	157.33%	187.42%	-54.13%	-33.95%
Invested Capital Growth	12.23%	-4.26%	42.69%	-8.34%	-18.19%	-10.41%	131.68%	24.68%	-24.29%	-25.28%	-37.35%
Revenue Q/Q Growth	0.66%	3.65%	-0.33%	-2.25%	1.76%	0.06%	33.96%	-0.56%	-9.59%	-7.19%	-6.49%
EBITDA Q/Q Growth	239.53%	-0.28%	1.57%	-104.03%	90.60%	51.55%	90.68%	-8.76%	-21.98%	-90.24%	-11,428.14%
EBIT Q/Q Growth	401.62%	-12.77%	-6.34%	-334.25%	60.45%	27.20%	102.14%	-9.26%	-25.33%	-1,149.71%	-405.38%
NOPAT Q/Q Growth	479.72%	121.71%	586.42%	-362.22%	62.40%	28.82%	118.02%	-16.93%	-29.75%	-40,650.06%	-419.73%
Net Income Q/Q Growth	153.81%	-16.47%	1,239.39%	-149.30%	25.10%	30.87%	122.78%	-18.16%	-29.06%	-724.70%	-505.08%
EPS Q/Q Growth	138.89%	139.47%	62.90%	-156.47%	24.77%	30.77%	122.01%	-17.91%	-27.56%	-1,366.67%	-486.00%
Operating Cash Flow Q/Q Growth	2.16%	-4.72%	71.21%	-45.55%	-45.31%	36.54%	-729.31%	137.82%	3.22%	11.26%	-11.05%
Free Cash Flow Firm Q/Q Growth	-101.56%	310.95%	117.26%	795.88%	-10.65%	25.75%	-126.20%	127.28%	25.29%	9.06%	46.70%
Invested Capital Q/Q Growth	20.92%	6.91%	5.92%	-4.81%	3.87%	3.79%	48.84%	14.06%	-1.06%	-6.91%	-30.72%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	25.59%	99.93%	99.79%	99.73%	99.76%	99.64%	22.37%	99.66%	99.28%	98.41%	20.26%
EBITDA Margin	2.73%	2.77%	2.81%	-0.08%	-0.35%	0.39%	8.94%	10.12%	6.48%	0.14%	-6.41%
Operating Margin	2.68%	0.74%	1.36%	-1.58%	-1.91%	-1.10%	8.31%	9.63%	5.58%	-1.25%	-8.01%
EBIT Margin	1.43%	1.47%	1.56%	-1.53%	-2.06%	-1.13%	8.35%	9.67%	5.58%	-1.21%	-8.01%
Profit (Net Income) Margin	0.65%	1.05%	4.49%	-1.93%	-6.80%	-1.45%	7.87%	6.63%	3.60%	-1.08%	-9.00%
Tax Burden Percent	119.09%	192.10%	902.16%	86.38%	231.06%	98.48%	99.09%	73.48%	70.59%	88.77%	113.58%
Interest Burden Percent	37.92%	37.20%	31.90%	146.00%	143.03%	130.61%	95.10%	93.32%	91.36%	100.85%	98.92%
Effective Tax Rate	-19.09%	-92.10%	-802.16%	0.00%	0.00%	0.00%	0.91%	26.52%	29.41%	0.00%	0.00%
Return on Invested Capital (ROIC)	11.37%	5.33%	40.03%	-3.02%	-4.24%	-2.90%	39.80%	36.43%	14.99%	-2.95%	-21.26%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.17%	1.21%	-55.97%	-12.54%	-69.80%	-12.13%	34.79%	29.17%	5.25%	3.33%	17.20%
Return on Net Nonoperating Assets (RNNOA)	-7.72%	0.63%	-20.11%	-3.87%	-25.07%	-4.73%	18.55%	13.23%	0.81%	-0.33%	-4.31%
Return on Equity (ROE)	3.65%	5.96%	19.92%	-6.89%	-29.31%	-7.63%	58.35%	49.66%	15.80%	-3.28%	-25.57%
Cash Return on Invested Capital (CROIC)	-0.16%	9.68%	4.85%	5.68%	15.77%	8.08%	-39.60%	14.47%	42.64%	25.98%	24.67%
Operating Return on Assets (OROA)	3.18%	3.24%	3.15%	-2.79%	-4.18%	-2.55%	25.71%	32.24%	13.81%	-2.56%	-16.26%
Return on Assets (ROA)	1.43%	2.32%	9.07%	-3.51%	-13.82%	-3.28%	24.23%	22.11%	8.91%	-2.29%	-18.27%
Return on Common Equity (ROCE)	3.63%	5.94%	19.86%	-6.88%	-29.19%	-7.59%	58.28%	49.66%	15.80%	-3.28%	-25.57%
Return on Equity Simple (ROE_SIMPLE)	3.52%	5.77%	16.37%	-7.23%	-34.40%	-7.87%	44.37%	41.19%	15.53%	-3.47%	0.00%
Net Operating Profit after Tax (NOPAT)	24	12	106	-9.02	-11	-6.41	138	198	80	-12	-59
NOPAT Margin	3.19%	1.43%	12.25%	-1.10%	-1.34%	-0.77%	8.23%	7.07%	3.94%	-0.88%	-5.60%
Net Nonoperating Expense Percent (NNEP)	24.53%	4.12%	96.00%	9.52%	65.56%	9.23%	5.01%	7.26%	9.74%	-6.29%	-38.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	43.21%	16.77%	-2.79%	-18.30%
Cost of Revenue to Revenue	74.41%	0.07%	0.21%	0.27%	0.24%	0.36%	77.63%	0.34%	0.72%	1.59%	79.74%
SG&A Expenses to Revenue	21.02%	21.57%	21.67%	22.07%	22.13%	20.78%	12.90%	11.56%	14.87%	17.36%	19.03%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	22.91%	99.19%	98.43%	101.31%	101.67%	100.73%	14.06%	90.03%	93.70%	99.66%	28.33%
Earnings before Interest and Taxes (EBIT)	11	12	13	-12	-17	-9.44	140	271	113	-16	-84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	21	23	24	-0.68	-2.85	3.23	150	284	131	1.94	-68
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.79	3.41	1.96	1.22	2.63	2,158.30	3,545.82	2.19	1.70	1.43	0.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	14.63	6.50	40.01	14,664.93	8,128.13	4.07	2.87	2.47	1.15
Price to Revenue (P/Rev)	0.70	0.62	0.54	0.33	0.52	398.35	629.22	0.35	0.39	0.44	0.25
Price to Earnings (P/E)	120.84	64.68	12.41	0.00	0.00	0.00	7,992.17	5.33	10.96	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.83%	1.55%	8.06%	0.00%	0.00%	0.00%	0.01%	18.77%	9.13%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.73	2.67	1.73	1.17	2.14	1,593.38	2,177.70	1.65	1.72	1.52	0.73
Enterprise Value to Revenue (EV/Rev)	0.81	0.70	0.62	0.41	0.61	398.42	629.33	0.35	0.39	0.39	0.15
Enterprise Value to EBITDA (EV/EBITDA)	29.70	25.17	22.20	0.00	0.00	103,138.96	7,037.93	3.51	6.00	268.32	0.00
Enterprise Value to EBIT (EV/EBIT)	56.64	47.65	40.03	0.00	0.00	0.00	7,532.94	3.67	6.97	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	25.37	49.01	5.09	0.00	0.00	0.00	7,643.78	5.02	9.87	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	34.07	19.31	11.86	15.89	90.10	12,249.74	0.00	7.42	3.16	4.33	3.25
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	26.96	42.03	19.69	12.20	18,629.36	0.00	12.63	3.47	5.01	2.28
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.63	0.57	0.42	0.38	0.43	0.36	0.63	0.02	0.01	0.01	0.00
Long-Term Debt to Equity	0.58	0.56	0.39	0.36	0.43	0.34	0.59	0.00	0.00	0.00	0.00
Financial Leverage	0.59	0.52	0.36	0.31	0.36	0.39	0.53	0.45	0.15	-0.10	-0.25
Leverage Ratio	2.54	2.57	2.20	1.96	2.12	2.32	2.41	2.25	1.77	1.43	1.40
Compound Leverage Factor	0.96	0.96	0.70	2.87	3.03	3.03	2.29	2.10	1.62	1.44	1.38
Debt to Total Capital	38.74%	36.43%	29.43%	27.60%	30.27%	26.49%	38.73%	1.63%	1.43%	1.04%	0.00%
Short-Term Debt to Total Capital	3.50%	0.94%	2.04%	1.74%	0.00%	1.15%	2.40%	1.63%	1.43%	1.04%	0.00%
Long-Term Debt to Total Capital	35.24%	35.49%	27.39%	25.86%	30.27%	25.34%	36.32%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.22%	0.23%	0.19%	0.22%	0.37%	0.25%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	61.05%	63.33%	70.38%	72.18%	69.36%	73.25%	61.27%	98.37%	98.57%	98.96%	100.00%
Debt to EBITDA	4.27	3.76	4.08	-121.96	-24.89	17.28	1.25	0.03	0.05	2.27	0.00
Net Debt to EBITDA	4.15	2.87	3.03	-98.48	-24.52	16.79	1.25	0.01	-0.08	-39.81	0.00
Long-Term Debt to EBITDA	3.89	3.66	3.80	-114.29	-24.89	16.53	1.18	0.00	0.00	0.00	0.00
Debt to NOPAT	3.65	7.32	0.94	-9.23	-6.45	-8.71	1.36	0.04	0.09	-0.37	0.00
Net Debt to NOPAT	3.55	5.59	0.69	-7.45	-6.36	-8.46	1.35	0.02	-0.13	6.54	0.00
Long-Term Debt to NOPAT	3.32	7.13	0.87	-8.65	-6.45	-8.33	1.28	0.00	0.00	0.00	0.00
Altman Z-Score	3.44	3.52	3.25	2.61	2.97	991.30	1,457.59	5.83	6.69	5.25	3.95
Noncontrolling Interest Sharing Ratio	0.35%	0.36%	0.31%	0.29%	0.40%	0.44%	0.12%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.84	2.12	2.21	2.28	2.15	1.96	2.54	2.43	2.67	2.78	3.78
Quick Ratio	1.74	2.00	2.11	2.13	2.00	1.84	2.48	2.31	2.50	2.53	3.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-0.34	22	13	17	41	18	-137	79	226	104	69
Operating Cash Flow to CapEx	772.02%	462.20%	890.39%	456.75%	188.50%	589.47%	-1,194.11%	1,525.72%	1,778.29%	1,378.43%	591.24%
Free Cash Flow to Firm to Interest Expense	-0.05	2.81	1.40	2.96	5.62	6.19	-20.00	4.35	23.05	47.44	30.94
Operating Cash Flow to Interest Expense	2.68	3.93	4.96	3.66	0.76	9.41	-12.47	7.40	25.31	54.90	21.77
Operating Cash Flow Less CapEx to Interest Expense	2.33	3.08	4.40	2.86	0.36	7.82	-13.51	6.91	23.89	50.92	18.09
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.22	2.21	2.02	1.83	2.03	2.26	3.08	3.33	2.48	2.12	2.03
Accounts Receivable Turnover	5.90	5.20	4.98	4.81	4.90	4.93	5.05	4.94	3.98	4.51	5.40
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	67.90	71.59	64.31	58.92	64.59	69.17	118.98	157.96	85.94	47.84	37.24
Accounts Payable Turnover	16.69	0.01	0.03	0.05	0.04	0.06	16.31	0.06	0.10	0.27	15.15
Days Sales Outstanding (DSO)	61.83	70.17	73.25	75.94	74.50	74.08	72.27	73.92	91.62	80.87	67.64
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	21.86	30,759.71	10,926.74	7,811.81	8,131.61	5,748.78	22.38	5,749.99	3,582.05	1,343.44	24.09
Cash Conversion Cycle (CCC)	39.97	-30,689.54	-10,853.48	-7,735.88	-8,057.11	-5,674.70	49.88	-5,676.07	-3,490.43	-1,262.57	43.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	228	218	311	285	233	209	485	604	457	342	214
Invested Capital Turnover	3.56	3.74	3.27	2.74	3.17	3.78	4.83	5.15	3.81	3.36	3.79
Increase / (Decrease) in Invested Capital	25	-9.72	93	-26	-52	-24	275	120	-147	-116	-128
Enterprise Value (EV)	621	582	540	334	499	333,242	1,055,169	995	786	521	157
Market Capitalization	534	515	465	266	429	333,187	1,054,982	991	796	598	265
Book Value per Share	$4.32	$4.58	$6.50	$6.00	$4.41	$0.00	$0.01	$12.11	$13.30	$12.73	$9.85
Tangible Book Value per Share	($1.14)	($0.02)	$0.87	$1.13	$0.29	$0.00	$0.00	$6.53	$7.90	$7.34	$7.06
Total Capital	231	239	337	301	234	211	486	459	474	423	323
Total Debt	89	87	99	83	71	56	188	7.50	6.79	4.41	0.00
Total Long-Term Debt	81	85	92	78	71	53	176	0.00	0.00	0.00	0.00
Net Debt	87	66	74	67	70	54	187	3.90	-10	-77	-109
Capital Expenditures (CapEx)	2.36	6.52	5.11	4.60	2.94	4.62	7.17	8.79	14	8.71	8.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	78	90	96	99	97	91	319	402	250	137	107
Debt-free Net Working Capital (DFNWC)	81	111	121	115	98	92	320	406	268	219	216
Net Working Capital (NWC)	73	109	114	110	98	90	309	398	261	215	216
Net Nonoperating Expense (NNE)	20	3.15	67	6.70	45	5.73	6.04	12	6.93	2.75	36
Net Nonoperating Obligations (NNO)	87	66	74	67	70	54	187	153	-10	-77	-109
Total Depreciation and Amortization (D&A)	9.95	11	11	12	14	13	9.85	13	18	18	17
Debt-free, Cash-free Net Working Capital to Revenue	10.21%	10.81%	11.06%	12.09%	11.78%	10.82%	19.03%	14.35%	12.40%	10.22%	10.16%
Debt-free Net Working Capital to Revenue	10.52%	13.29%	14.01%	14.05%	11.91%	11.01%	19.10%	14.47%	13.25%	16.30%	20.47%
Net Working Capital to Revenue	9.47%	13.02%	13.21%	13.41%	11.91%	10.72%	18.40%	14.21%	12.91%	15.97%	20.47%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.14	$0.25	$1.07	($0.48)	($1.61)	($0.36)	$3.60	$5.09	$2.07	($0.44)	($2.93)
Adjusted Weighted Average Basic Shares Outstanding	31.51M	32.13M	35.02M	35.66M	35.82M	75.03M	36.69M	37.01M	35.16M	33.38M	32.41M
Adjusted Diluted Earnings per Share	$0.14	$0.15	$1.01	($0.48)	($1.61)	($0.36)	$3.53	$5.02	$2.05	($0.44)	($2.93)
Adjusted Weighted Average Diluted Shares Outstanding	32.16M	36.25M	36.17M	35.66M	35.82M	75.03M	37.39M	37.54M	35.48M	33.38M	32.41M
Adjusted Basic & Diluted Earnings per Share	$0.14	$0.00	$0.00	$0.00	$0.00	($0.36)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.61M	32.98M	36.43M	36.14M	36.86M	36.09M	38.06M	36.82M	34.73M	32.81M	32.32M
Normalized Net Operating Profit after Tax (NOPAT)	17	22	20	8.61	4.04	9.20	143	204	82	-3.80	-1.97
Normalized NOPAT Margin	2.27%	2.63%	2.36%	1.05%	0.49%	1.10%	8.51%	7.27%	4.06%	-0.28%	-0.19%
Pre Tax Income Margin	0.54%	0.55%	0.50%	-2.23%	-2.94%	-1.47%	7.94%	9.03%	5.09%	-1.22%	-7.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.61	1.59	1.47	-2.17	-2.32	-3.27	20.40	14.97	11.47	-7.43	-38.10
NOPAT to Interest Expense	3.60	1.55	11.54	-1.57	-1.51	-2.22	20.11	10.95	8.10	-5.40	-26.67
EBIT Less CapEx to Interest Expense	1.26	0.74	0.91	-2.98	-2.73	-4.86	19.36	14.48	10.05	-11.41	-41.78
NOPAT Less CapEx to Interest Expense	3.25	0.70	10.99	-2.37	-1.91	-3.82	19.06	10.46	6.68	-9.38	-30.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	9.97%	0.00%	3.14%	-7.60%	-2.81%	-9.50%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	9.97%	0.00%	3.14%	-39.41%	-2.81%	-9.50%	0.00%	18.97%	79.38%	-256.32%	-7.20%

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	32,812,580.00	32,783,168.00	32,761,995.00	32,759,952.00	32,318,741.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	32,812,580.00	32,783,168.00	32,761,995.00	32,759,952.00	32,318,741.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.01	-0.20	-0.15	-2.53	-0.13
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-30.47%	-33.75%	-39.11%	-37.16%	-28.75%	-25.14%	-22.62%	-19.34%	-20.65%	-23.61%	-17.84%
EBITDA Growth	-55.42%	-65.22%	-81.95%	-136.04%	-70.33%	-99.49%	-56.67%	87.73%	-125.33%	-13,645.20%	-112.64%
EBIT Growth	-61.37%	-72.18%	-90.52%	-153.99%	-85.96%	-131.53%	-126.07%	69.41%	-309.92%	-1,763.03%	-299.33%
NOPAT Growth	-64.21%	-76.97%	-93.37%	-154.25%	-83.88%	-125.69%	-132.08%	69.49%	-294.39%	-1,985.79%	-325.28%
Net Income Growth	-63.18%	-75.11%	-90.85%	-175.19%	-80.06%	-141.52%	-118.20%	58.51%	-286.85%	-2,109.67%	-770.61%
EPS Growth	-61.29%	-71.72%	-90.12%	-178.33%	-77.78%	-146.43%	-125.00%	57.45%	-287.50%	-1,869.23%	-600.00%
Operating Cash Flow Growth	-50.00%	179.49%	-87.17%	-30.90%	-89.38%	100.71%	-5.49%	-94.88%	169.26%	-24.74%	-16.09%
Free Cash Flow Firm Growth	148.38%	297.72%	967.79%	-1.71%	20.55%	-27.48%	-6.40%	-70.33%	-44.58%	-31.52%	-1.14%
Invested Capital Growth	-12.72%	-24.29%	-22.49%	-27.67%	-20.58%	-25.28%	-27.73%	-11.38%	-15.83%	-37.35%	-38.60%
Revenue Q/Q Growth	-18.20%	-6.39%	-8.42%	-10.39%	-7.26%	-1.64%	-5.33%	-6.59%	-8.76%	-5.32%	1.81%
EBITDA Q/Q Growth	-37.63%	-27.35%	-51.22%	-262.35%	151.35%	-98.74%	647.00%	-147.68%	-4.27%	-3,547.07%	99.30%
EBIT Q/Q Growth	-42.68%	-33.16%	-69.38%	-557.58%	114.91%	-250.04%	73.00%	-467.21%	-1.07%	-1,103.68%	94.21%
NOPAT Q/Q Growth	-46.18%	-29.87%	-77.21%	-730.72%	116.00%	-211.73%	71.54%	-499.69%	-1.95%	-1,098.81%	94.20%
Net Income Q/Q Growth	-39.98%	-29.46%	-70.21%	-696.21%	115.92%	-246.89%	86.94%	-1,258.98%	28.31%	-1,637.10%	94.86%
EPS Q/Q Growth	-40.00%	-22.22%	-71.43%	-687.50%	117.02%	-262.50%	84.62%	-900.00%	25.00%	-1,606.67%	94.53%
Operating Cash Flow Q/Q Growth	-41.04%	-82.83%	-50.22%	1,270.84%	-90.93%	224.42%	-76.56%	-25.77%	376.97%	-9.32%	-73.86%
Free Cash Flow Firm Q/Q Growth	-38.72%	93.41%	-11.82%	-5.95%	-24.85%	16.35%	13.82%	-70.19%	40.40%	43.77%	64.30%
Invested Capital Q/Q Growth	-10.50%	-1.06%	0.85%	-20.02%	-1.72%	-6.91%	-1.24%	-1.92%	-6.66%	-30.72%	-3.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	99.47%	98.99%	99.66%	94.45%	99.52%	100.07%	99.99%	99.99%	100.34%	-255.43%	99.97%
EBITDA Margin	5.59%	4.33%	2.32%	-4.20%	2.33%	0.03%	1.27%	-0.65%	-0.74%	-28.61%	-0.20%
Operating Margin	4.59%	3.24%	0.77%	-5.65%	0.91%	-1.11%	-0.33%	-2.14%	-2.39%	-30.24%	-1.72%
EBIT Margin	4.56%	3.26%	1.09%	-5.59%	0.90%	-1.37%	-0.35%	-2.15%	-2.38%	-30.22%	-1.72%
Profit (Net Income) Margin	2.90%	2.18%	0.71%	-4.72%	0.81%	-1.21%	-0.17%	-2.43%	-1.91%	-35.03%	-1.77%
Tax Burden Percent	65.70%	69.69%	72.97%	82.05%	75.39%	95.89%	54.51%	116.23%	84.69%	116.40%	114.25%
Interest Burden Percent	96.71%	96.23%	88.87%	102.99%	119.67%	92.12%	86.69%	97.40%	94.82%	99.56%	90.17%
Effective Tax Rate	34.30%	30.31%	27.03%	0.00%	24.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	13.58%	8.60%	1.87%	-14.01%	2.38%	-2.61%	-0.73%	-5.07%	-5.58%	-80.31%	-4.44%
ROIC Less NNEP Spread (ROIC-NNEP)	12.52%	8.15%	2.62%	12.89%	1.14%	0.48%	-1.20%	-1.58%	-4.82%	-45.03%	-2.98%
Return on Net Nonoperating Assets (RNNOA)	1.40%	1.26%	0.43%	-0.27%	-0.08%	-0.05%	0.11%	0.27%	0.91%	11.29%	0.76%
Return on Equity (ROE)	14.98%	9.86%	2.29%	-14.28%	2.30%	-2.66%	-0.62%	-4.79%	-4.67%	-69.02%	-3.68%
Cash Return on Invested Capital (CROIC)	36.42%	42.64%	34.62%	34.12%	22.95%	25.98%	28.59%	10.59%	13.83%	24.67%	25.32%
Operating Return on Assets (OROA)	12.81%	8.06%	2.48%	-12.82%	1.99%	-2.90%	-0.73%	-4.43%	-4.72%	-61.39%	-3.35%
Return on Assets (ROA)	8.14%	5.41%	1.61%	-10.83%	1.80%	-2.56%	-0.34%	-5.01%	-3.79%	-71.14%	-3.45%
Return on Common Equity (ROCE)	14.98%	9.86%	2.29%	-14.28%	2.30%	-2.66%	-0.62%	-4.79%	-4.67%	-69.02%	-3.68%
Return on Equity Simple (ROE_SIMPLE)	21.80%	0.00%	9.80%	1.93%	-0.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	13	9.36	2.13	-13	2.15	-2.40	-0.68	-4.10	-4.18	-50	-2.91
NOPAT Margin	3.02%	2.26%	0.56%	-3.96%	0.68%	-0.78%	-0.23%	-1.50%	-1.67%	-21.17%	-1.21%
Net Nonoperating Expense Percent (NNEP)	1.06%	0.45%	-0.75%	-26.90%	1.24%	-3.08%	0.47%	-3.49%	-0.76%	-35.28%	-1.46%
Return On Investment Capital (ROIC_SIMPLE)	-	1.97%	-	-	-	-0.57%	-0.16%	-0.99%	-1.02%	-15.53%	-0.93%
Cost of Revenue to Revenue	0.53%	1.01%	0.34%	5.55%	0.48%	-0.07%	0.01%	0.01%	-0.34%	355.43%	0.03%
SG&A Expenses to Revenue	15.74%	16.30%	16.68%	17.73%	17.23%	17.93%	17.89%	18.26%	18.75%	21.65%	19.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	94.88%	95.75%	98.89%	100.10%	98.61%	101.18%	100.32%	102.13%	102.73%	-224.91%	101.70%
Earnings before Interest and Taxes (EBIT)	20	13	4.15	-19	2.83	-4.25	-1.04	-5.88	-5.95	-72	-4.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	25	18	8.79	-14	7.33	0.09	3.74	-1.78	-1.86	-68	-0.47
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.89	1.70	1.41	1.10	1.07	1.43	1.17	1.04	1.14	0.82	0.97
Price to Tangible Book Value (P/TBV)	3.20	2.87	2.34	1.89	1.87	2.47	2.01	1.79	1.96	1.15	1.36
Price to Revenue (P/Rev)	0.40	0.39	0.37	0.31	0.31	0.44	0.39	0.36	0.41	0.25	0.30
Price to Earnings (P/E)	8.67	10.96	14.34	56.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	11.54%	9.13%	6.97%	1.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.90	1.72	1.41	1.11	1.08	1.52	1.21	1.05	1.18	0.73	0.96
Enterprise Value to Revenue (EV/Rev)	0.39	0.39	0.37	0.26	0.27	0.39	0.32	0.29	0.32	0.15	0.20
Enterprise Value to EBITDA (EV/EBITDA)	5.24	6.00	7.21	11.16	19.96	268.32	0.00	35.43	613.21	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	5.84	6.97	8.99	22.02	256.17	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	7.77	9.87	13.24	46.59	13,629.97	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	3.66	3.16	3.16	2.43	3.68	4.33	3.41	8.33	6.75	3.25	4.19
Enterprise Value to Free Cash Flow (EV/FCFF)	4.87	3.47	3.55	2.74	4.17	5.01	3.55	9.29	7.83	2.28	2.87
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.01	0.01	0.01	0.02	0.01	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.11	0.15	0.16	-0.02	-0.07	-0.10	-0.09	-0.17	-0.19	-0.25	-0.25
Leverage Ratio	1.78	1.77	1.71	1.51	1.46	1.43	1.38	1.36	1.36	1.40	1.41
Compound Leverage Factor	1.72	1.71	1.52	1.56	1.75	1.32	1.20	1.32	1.29	1.39	1.27
Debt to Total Capital	1.45%	1.43%	0.87%	0.93%	1.50%	1.04%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	1.45%	1.43%	0.87%	0.93%	0.95%	1.04%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.55%	98.57%	99.13%	99.07%	98.50%	98.96%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.04	0.05	0.05	0.11	0.32	2.27	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-0.04	-0.08	-0.01	-1.76	-2.90	-39.81	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.12	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.06	0.09	0.08	0.46	221.48	-0.37	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-0.07	-0.13	-0.02	-7.34	-1,977.54	6.54	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	80.65	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.38	6.21	5.95	5.25	4.97	5.32	5.01	4.93	5.21	4.05	4.43
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.43	2.67	3.02	3.07	2.79	2.78	2.98	3.21	3.45	3.78	3.29
Quick Ratio	2.31	2.50	2.82	2.83	2.56	2.53	2.76	2.94	3.27	3.55	3.12
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	81	156	138	129	97	113	129	38	54	78	127
Operating Cash Flow to CapEx	2,052.88%	419.97%	271.99%	2,892.28%	664.59%	957.49%	301.22%	214.39%	918.03%	861.55%	326.95%
Free Cash Flow to Firm to Interest Expense	120.65	266.40	297.98	227.94	176.91	186.20	237.29	69.96	96.99	136.50	224.66
Operating Cash Flow to Interest Expense	105.10	20.60	13.01	145.07	13.58	39.86	10.46	7.68	36.18	32.11	8.41
Operating Cash Flow Less CapEx to Interest Expense	99.98	15.70	8.23	140.06	11.54	35.70	6.99	4.10	32.24	28.38	5.84
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.81	2.48	2.26	2.29	2.22	2.12	2.05	2.06	1.99	2.03	1.95
Accounts Receivable Turnover	4.37	3.98	3.61	4.33	4.42	4.51	4.36	5.37	5.30	5.40	5.05
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	99.69	85.94	69.27	58.48	52.43	47.84	44.68	41.66	39.39	37.24	36.15
Accounts Payable Turnover	10.45	0.10	12.74	16.20	18.25	0.27	0.32	0.03	0.00	15.15	16.18
Days Sales Outstanding (DSO)	83.43	91.62	101.16	84.25	82.59	80.87	83.73	67.95	68.82	67.64	72.21
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	34.94	3,582.05	28.65	22.53	20.00	1,343.44	1,132.84	14,162.49	0.00	24.09	22.56
Cash Conversion Cycle (CCC)	48.49	-3,490.43	72.51	61.72	62.59	-1,262.57	-1,049.12	-14,094.54	68.82	43.55	49.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	462	457	467	374	367	342	338	331	309	214	207
Invested Capital Turnover	4.50	3.81	3.32	3.54	3.49	3.36	3.13	3.39	3.34	3.79	3.68
Increase / (Decrease) in Invested Capital	-67	-147	-136	-143	-95	-116	-130	-43	-58	-128	-130
Enterprise Value (EV)	880	786	657	416	397	521	408	347	366	157	198
Market Capitalization	888	796	658	481	454	598	489	428	465	265	304
Book Value per Share	$13.12	$13.30	$13.68	$12.63	$12.56	$12.73	$12.75	$12.57	$12.46	$9.85	$9.68
Tangible Book Value per Share	$7.74	$7.90	$8.21	$7.32	$7.18	$7.34	$7.41	$7.30	$7.25	$7.06	$6.91
Total Capital	477	474	472	443	431	423	418	412	408	323	313
Total Debt	6.91	6.79	4.10	4.10	6.45	4.41	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	2.35	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-7.39	-10	-1.14	-66	-58	-77	-81	-81	-99	-109	-106
Capital Expenditures (CapEx)	3.43	2.88	2.21	2.85	1.12	2.53	1.89	1.97	2.19	2.12	1.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	254	250	258	162	156	137	135	132	110	107	102
Debt-free Net Working Capital (DFNWC)	269	268	263	232	220	219	216	213	210	216	208
Net Working Capital (NWC)	262	261	259	228	216	215	216	213	210	216	208
Net Nonoperating Expense (NNE)	0.53	0.32	-0.56	2.61	-0.40	1.35	-0.19	2.56	0.59	33	1.36
Net Nonoperating Obligations (NNO)	-7.39	-10	-1.14	-66	-58	-77	-81	-81	-99	-109	-106
Total Depreciation and Amortization (D&A)	4.54	4.47	4.64	4.72	4.50	4.34	4.77	4.10	4.09	3.83	3.67
Debt-free, Cash-free Net Working Capital to Revenue	11.38%	12.40%	14.51%	10.29%	10.77%	10.22%	10.77%	11.04%	9.80%	10.16%	10.20%
Debt-free Net Working Capital to Revenue	12.02%	13.25%	14.81%	14.71%	15.19%	16.30%	17.18%	17.85%	18.59%	20.47%	20.73%
Net Working Capital to Revenue	11.71%	12.91%	14.57%	14.45%	14.91%	15.97%	17.18%	17.85%	18.59%	20.47%	20.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.37	$0.28	$0.08	($0.47)	$0.08	($0.13)	($0.02)	($0.20)	($0.15)	($2.56)	($0.14)
Adjusted Weighted Average Basic Shares Outstanding	34.95M	35.16M	34.22M	33.96M	33.02M	33.38M	32.28M	32.49M	32.52M	32.41M	31.47M
Adjusted Diluted Earnings per Share	$0.36	$0.28	$0.08	($0.47)	$0.08	($0.13)	($0.02)	($0.20)	($0.15)	($2.56)	($0.14)
Adjusted Weighted Average Diluted Shares Outstanding	35.15M	35.48M	34.60M	33.96M	33.06M	33.38M	32.28M	32.49M	32.52M	32.41M	31.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	35.15M	34.73M	34.77M	33.81M	32.92M	32.81M	32.78M	32.76M	32.76M	32.32M	32.33M
Normalized Net Operating Profit after Tax (NOPAT)	14	10.00	3.26	-12	2.90	2.27	0.96	-3.69	-0.21	0.97	-2.21
Normalized NOPAT Margin	3.10%	2.41%	0.86%	-3.50%	0.92%	0.73%	0.33%	-1.35%	-0.08%	0.41%	-0.92%
Pre Tax Income Margin	4.41%	3.13%	0.97%	-5.76%	1.08%	-1.26%	-0.31%	-2.09%	-2.25%	-30.09%	-1.55%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	30.14	23.00	8.98	-33.44	5.15	-6.99	-1.91	-10.71	-10.69	-125.98	-7.30
NOPAT to Interest Expense	19.94	15.96	4.61	-23.67	3.91	-3.95	-1.26	-7.47	-7.52	-88.25	-5.13
EBIT Less CapEx to Interest Expense	25.02	18.09	4.20	-38.46	3.11	-11.15	-5.38	-14.30	-14.63	-129.71	-9.87
NOPAT Less CapEx to Interest Expense	14.82	11.06	-0.17	-28.69	1.87	-8.12	-4.73	-11.05	-11.46	-91.97	-7.70
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	60.74%	79.38%	70.31%	500.28%	-2,245.67%	-256.32%	-176.21%	-195.41%	-28.01%	-7.20%	-12.56%

Financials Breakdown Chart

Key Financial Trends

Cross Country Healthcare (NASDAQ: CCRN) has seen a dramatic shift from the highly profitable staffing environment of 2022-2023 to a much more difficult operating backdrop in 2025-2026. The latest quarter shows a company that is still generating positive operating cash flow, but revenue, profitability, and balance sheet strength are all noticeably weaker than the peaks seen two years ago.

In Q1 2026, revenue was $241.1 million, up slightly from $236.8 million in Q4 2025, but still well below the $293.4 million posted in Q1 2025 and far under the $379.2 million generated in Q1 2024. That tells investors the business is still working through a lower-demand or lower-rate environment compared with prior years.

Profitability remains under pressure. The company reported a Q1 2026 net loss of $4.3 million, an improvement from the $82.9 million loss in Q4 2025, but still a loss. Operating income was also negative at $4.2 million, compared with a much worse loss in Q4 2025. The key issue is that operating expenses, especially “other operating expenses,” remain extremely high relative to revenue.

Cash flow is a mixed picture. Q1 2026 operating cash flow was $4.8 million, which is positive but much lower than the $18.2 million generated in Q4 2025 and the $5.7 million generated in Q1 2025. The company also spent $1.5 million on capital expenditures, and financing cash flow was sharply negative due to share repurchases and debt activity.

From a balance sheet standpoint, CCRN still has liquidity, but it has become less robust over time. Cash and equivalents totaled $105.6 million at the end of Q1 2026, up from $80.7 million in Q1 2025, but down from the company’s much stronger cash position in 2023. Total assets were $451.1 million and total liabilities were $138.3 million, leaving equity of $312.8 million.

Compared with 2023, the business has clearly reset lower. In Q1 2023, CCRN posted revenue of $622.7 million and net income of $29.4 million. By Q1 2026, revenue had dropped by more than half and profits had turned negative. That is a major change in the earnings profile investors should not ignore.

Operating cash flow remained positive in Q1 2026 at $4.8 million, showing the company is still bringing in cash from core operations.
Cash and equivalents rose sequentially to $105.6 million, giving CCRN a reasonable liquidity cushion.
Q1 2026 losses improved sharply versus Q4 2025, suggesting the quarter was less severe than the prior period’s earnings collapse.
Debt balances appear manageable relative to total equity, with total liabilities at $138.3 million versus equity of $312.8 million.
Revenue was modestly higher sequentially than Q4 2025, but still well below year-ago levels.
Capital spending was relatively modest at $1.5 million in Q1 2026, which helps preserve cash.
The company continued buying back shares, which can support EPS over time, but only if fundamentals improve.
Net income remained negative at $(4.3) million in Q1 2026, extending the loss trend.
Operating income was negative at $(4.2) million, indicating the core business is not yet consistently profitable.
Revenue remains far below 2023 levels, showing a major step down in business activity from the peak staffing environment.

Bottom line: CCRN is no longer the high-growth, high-profit story it was in 2023. The company still has cash and is generating positive operating cash flow, but the trend in revenue and earnings has weakened considerably. Investors will want to watch whether management can stabilize margins and rebuild operating profitability before the market rerates the stock meaningfully.

07/08/26 08:43 PM ETAI Generated. May Contain Errors.

Cross Country Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cross Country Healthcare's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cross Country Healthcare's net income appears to be on an upward trend, with a most recent value of -$94.85 million in 2025, falling from $4.95 million in 2015. The previous period was -$14.56 million in 2024. Find out what analysts predict for Cross Country Healthcare in the coming months.

Cross Country Healthcare's total operating income in 2025 was -$84.41 million, based on the following breakdown:

Total Gross Profit: $213.57 million
Total Operating Expenses: $298.63 million

Over the last 10 years, Cross Country Healthcare's total revenue changed from $767.42 million in 2015 to $1.05 billion in 2025, a change of 37.4%.

Cross Country Healthcare's total liabilities were at $126.13 million at the end of 2025, a 25.9% decrease from 2024, and a 43.8% decrease since 2015.

In the past 10 years, Cross Country Healthcare's cash and equivalents has ranged from $1.03 million in 2019 to $108.74 million in 2025, and is currently $108.74 million as of their latest financial filing in 2025.

Over the last 10 years, Cross Country Healthcare's book value per share changed from 4.32 in 2015 to 9.85 in 2025, a change of 127.9%.

Related Companies

Financial statements for NASDAQ:CCRN last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cross Country Healthcare (CCRN) Financials

Financials Breakdown Chart

Key Financial Trends

Cross Country Healthcare Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cross Country Healthcare (CCRN) Financials

Annual Income Statements for Cross Country Healthcare

Quarterly Income Statements for Cross Country Healthcare

Annual Cash Flow Statements for Cross Country Healthcare

Quarterly Cash Flow Statements for Cross Country Healthcare

Annual Balance Sheets for Cross Country Healthcare

Quarterly Balance Sheets for Cross Country Healthcare

Annual Metrics And Ratios for Cross Country Healthcare

Quarterly Metrics And Ratios for Cross Country Healthcare

Financials Breakdown Chart

Key Financial Trends

Cross Country Healthcare Financials - Frequently Asked Questions

When does Cross Country Healthcare's financial year end?

How has Cross Country Healthcare's net income changed over the last 10 years?

What is Cross Country Healthcare's operating income?

How has Cross Country Healthcare's revenue changed over the last 10 years?

How much debt does Cross Country Healthcare have?

How much cash does Cross Country Healthcare have?

How has Cross Country Healthcare's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools